Prostaglandin e receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties

Breast Cancer Research and Treatment

Volumn 143, Issue 1, 2014, Pages 19-31

  Kundu, Namita ^a,b   Ma, Xinrong ^b   Kochel, Tyler ^b   Goloubeva, Olga ^b   Staats, Paul ^a,b   Thompson, Keyata ^b   Martin, Stuart ^b   Reader, Jocelyn ^b   Take, Yukinori ^c   Collin, Peter ^d   Fulton, Amy ^a,b,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c RaQualia Pharma Inc   (Japan)

^d Baltimore Veterans Administration ^*  (United States)

^e Baltimore Veterans Administration   (United States)

Author keywords

Breast cancer; COX 2; Prostaglandin E; Prostaglandin E receptor EP4; Stem cells; Tumor initiating cells

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; CYCLOOXYGENASE 2; FRONDOSIDE A; HERMES ANTIGEN; INDOMETACIN; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E RECEPTOR 4 INHIBITOR; PROSTAGLANDIN INHIBITOR; RQ 08; RQ 15986; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL SUBPOPULATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; EP4 GENE; FEMALE; GENE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MICE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84892822529     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2779-4     Document Type: Article

References (35)

1. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632-635
2. Kerikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102:627-637
3. Reader JC, Holt D, Fulton AM (2011) Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 30:449-463
4. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T et al (2002) Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 62:28-32
5. Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E (2010) Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 70:1606-1615
6. Kim J, Lakshmikanthan V, Frilot N, Daaka Y (2010) Prostaglandin E2 promotes lung cancer cell migration via EP4-B arrestin1-c-Src signalsome. Mol Cancer Res 8:569-577
7. Zhang Y, Ritzenthaler J, Sun X, Roman J, Han S (2009) Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res 69:896-904
8. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN (2006) Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103:1492-1499
9. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, Williams AC, Paraskeva C (2006) Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66:3106-3113
10. Rundhaug JE, Simper MS, Surh I, Fischer SM (2011) The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 30:465-480
11. Wu J, Zhang Y, Frilot N, Kim JI, Kim W-J, Daaka Y (2011) Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J Biol Chem 286:33954-33962
12. Subbaramaiah K, Hudis C, Chang S-H, Hla T, Dannenberg AJ (2008) EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: evidence of a BRCA1 and p300 exchange. J Biol Chem 283:3433-3444
13. Ma X, Kundu N, Rifat S, Walser T, Fulton AM (2006) Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 66:2923-2927
14. Fulton AM, Ma X, Kundu N (2006) Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 66:9794-9797
15. Timoshenko A, Guoziong X, Chakrabarti S, Lala P, Chakraborty C (2003) Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 289:265-274
16. Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S et al (2008) Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol 7:299-312
17. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E et al (2006) Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 66:9665-9672
18. 2 signaling. Cancer Discov 2:840-855
19. Murase A, Taniguchi Y, Tonai-Kachi H, Nakao K, Takada J (2007) In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci 82:226-232
20. Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM (2011) Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat 132:1001-1008
21. Kundu N, Ma X, Walser T, Goloubeva O, Ostrand-Rosenberg S, Fulton AM (2009) Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 117:235-242
22. Ma X, Kundu N, Ioffe O, Goloubeva O, Konger R, Baquet C, Gimotty P, Fulton AM (2010) Prostaglandin E receptor EP1 suppresses metastasis, is associated with better survival and may contribute to breast cancer disparities. Mol Cancer Res 8:1310-1318
23. 2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2:e22647
24. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
25. Weng D, Penzner JH, Song B, Koido S, Calderwood SK, Gong J (2012) Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. Breast Cancer Res 14:R18
26. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109:2784-2789
27. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR et al (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84-96
28. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survival chemotherapy. Breast Cancer Res 10:R25
29. Holt D, Ma X, Kundu N, Fulton AM (2011) Prostaglandin E2 (PGE2) suppresses natural killer cell function through the PGE2 receptor EP4. Cancer Immunol Immunother 60:1577-1586
30. Holt DH, Ma X, Kundu N, Collin PD, Fulton AM (2012) Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 35:179-188
31. Boniface K, Bak-Jensen K, Li Y, Blumenschein W, McGeachy M, McClanahan T et al (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206:535-548
32. Sharma S, Yang S, Zhu L, Reckamp K, Gardner B, Baratelli F (2005) Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65:5211-5225
33. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K et al (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 15:633-640
34. Rudnick JA, Arendt LM, Klebba I, Hinds JW, Iyer V, Gupta PB, Naber SP, Kuperwasser C (2011) Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS One 6:e24605
35. Singh B, Cook DR, Vincent L, Hall CS, Lucci A (2011) Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res 168:e39-e49